BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/14/2025 8:23:18 AM | Browse: 35 | Download: 120
 |
Received |
|
2025-06-26 15:25 |
|
Peer-Review Started |
|
2025-06-30 00:44 |
|
First Decision by Editorial Office Director |
|
2025-08-14 07:05 |
|
Return for Revision |
|
2025-08-14 07:05 |
|
Revised |
|
2025-08-28 04:49 |
|
Publication Fee Transferred |
|
2025-08-29 15:02 |
|
Second Decision by Editor |
|
2025-10-11 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-23 10:30 |
|
Articles in Press |
|
2025-10-23 10:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-07 06:17 |
|
Publish the Manuscript Online |
|
2025-11-14 08:23 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Dong An, Xin-Qin Li, He Zhang, Qian-You Jia, Yue-Hong Zhang and Gui-Gui Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82305205 |
| Young Elite Scientists Sponsorship Program by CACM |
CACM-2023-QNRC2-A05 |
| the Safeguard Project of Guang'anmen Hospital, China Academy of Chinese Medical Sciences |
GAMHH9324001 |
| the Special Fund for Outstanding Young Scientific Talent Training of the Fundamental Research Business Expenses of the China Academy of Chinese Medical Sciences |
ZZ18-YQ-011 |
|
| Corresponding Author |
Xue-Dong An, PhD, Department of Endocrinology, Guang’anmen Hospital, No. 5 North Line Pavilion, Xicheng District, Beijing 100053, China. doctor_anxd@163.com |
| Key Words |
Systematic review; Cardiovascular and renal disease; Type 2 diabetes mellitus; Nonsteroidal mineralocorticoid receptor antagonists; Sodium-glucose cotransporter-2 inhibitors; Glucagon-like peptide-1 receptor agonists |
| Core Tip |
Type 2 diabetes mellitus (T2DM), as one of the most common chronic metabolic diseases, is also one of the most significant risk factors for cardiovascular disease (CVD) and chronic kidney disease (CKD). GLP-1 receptor agonists (GLP-1RA), SGLT2 inhibitors (SGLT2i), and nonsteroidal mineralocorticoid receptor antagonists (nsMRA) have emerged as novel therapeutic agents to comprehensively manage T2DM -related CVD and CKD. We conducted a network meta-analysis to compare the efficacy and safety of GLP-1RAs, SGLT2i, and nsMRA in patients with T2DM. |
| Publish Date |
2025-11-14 08:23 |
| Citation |
An XD, Li XQ, Zhang H, Jia QY, Zhang YH, Yang GG. Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus. World J Diabetes 2025; 16(11): 111280 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i11/111280.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i11.111280 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
